login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NOVAVAX INC (NVAX) Stock News
USA
-
Nasdaq
- NASDAQ:NVAX -
US6700024010
-
Common Stock
6.66
USD
-0.02 (-0.3%)
Last: 12/19/2025, 8:06:27 PM
6.69
USD
+0.03 (+0.45%)
After Hours:
12/19/2025, 8:06:27 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NVAX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Zacks Investment Research
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
9 days ago - By: The Motley Fool
Why I Wouldn't Touch Novavax With a 10-Foot Pole
12 days ago - By: Zacks Investment Research
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
18 days ago - By: Zacks Investment Research
- Mentions:
PFE
MRNA
BNTX
PCVX
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
19 days ago - By: Investor's Business Daily
- Mentions:
PFE
MRNA
BNTX
DVAX
...
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths
a month ago - By: Stocktwits
Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale
a month ago - By: Zacks Investment Research
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
a month ago - By: Zacks Investment Research
- Mentions:
SNY
ANIP
ARQT
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
a month ago - By: Stocktwits
- Mentions:
IWMW
IWV
Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance
a month ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
2 months ago - By: Benzinga
An Overview of Novavax's Earnings
3 months ago - By: Zacks Investment Research
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
3 months ago - By: Novavax, Inc.
Novavax Announces Progress on Sanofi Agreement
2 months ago - By: Zacks Investment Research
- Mentions:
ANIK
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
3 months ago - By: Zacks Investment Research
Here's Why Novavax (NVAX) Fell More Than Broader Market
2 months ago - By: Novavax, Inc.
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
2 months ago - By: Novavax, Inc.
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
2 months ago - By: Stocktwits
- Mentions:
IWMW
ISCB
Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity
2 months ago - By: Novavax, Inc.
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
3 months ago - By: Stocktwits
- Mentions:
SNY
Novavax Amends Deal With Sanofi, Broadens Partnership
3 months ago - By: Investor's Business Daily
- Mentions:
PFE
MRNA
BNTX
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
3 months ago - By: Investor's Business Daily
- Mentions:
PFE
BNTX
MRNA
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut
Please enable JavaScript to continue using this application.